This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

July 2 Premarket Briefing: 10 Things You Should Know

Here are 10 things you should know for Wednesday, July 2:

1. -- U.S. stock futures were rising on greater manufacturing activity in the U.S. and China and as the Dow Jones Industrial Average storms toward 17,000.

European and Asian stocks rose on Tuesday. In Tokyo, the Nikkei 225 index gained 0.3%

2. -- The economic calendar in the U.S. on Wednesday includes the ADP National Employment Report for June at 8:15 a.m. EDT, and factory orders for May at 10 a.m.

3. -- U.S. stocks on Tuesday rose with the Dow moving within reach of the historic 17,000-level and the S&P 500 blazing a new intraday record high, both energized by data from Detroit carmakers and signs of a Chinese economy clunking back into gear.

The Dow spiked more than 1%, around 2 points short of 17,000, on Tuesday afternoon before settling 0.77% higher at 16,956.07. 

Likewise, the S&P 500 jumped to an intraday record high of 1,978.58 earlier in Tuesday's session but receded to 1,973.32, though still up 0.67%. The Nasdaq surged 1.14% to 4,458.65.

4. -- Jamie Dimon, CEO of JPMorgan Chase (JPM), said he has throat cancer.

"I wanted to let you know that I have just been diagnosed with throat cancer," Dimon said in memo sent to employees and shareholders. " The good news is that the prognosis from my doctors is excellent, the cancer was caught quickly, and my condition is curable. Following thorough tests that included a CAT scan, PET scan and a biopsy, the cancer is confined to the original site and the adjacent lymph nodes on the right side of my neck. Importantly, there is no evidence of cancer elsewhere in my body."

Dimon, 58 years old, said he plans to remain on the job and be actively involved in key decisions at the bank while undergoing radiation and chemotherapy treatment. The eight-week treatment will begin soon at Memorial Sloan Kettering Hospital in New York.

"While the treatment will curtail my travel during this period, I have been advised that I will be able to continue to be actively involved in our business, and we will continue to run the company as normal," Dimon said.

5. -- Fidelity Investments told investors outside the U.S. they can't buy mutual funds after July 31.

Fidelity informed about 60,000 customers, or about 0.3% of account holders, of the change in a letter, Stephen Austin, a spokesman, told Bloomberg. The clients won't be forced to sell existing holdings and will still be allowed to reinvest dividends in their funds.

The announcement reflects "a continually evolving global regulatory environment and is not in response to any specific issue, regulatory or otherwise," Austin told Bloomberg.

6. -- Roche subsidiary Genentech agreed to purchase U.S. biotechnology firm Seragon Pharmaceuticals for up to $1.725 billion in cash and contingency payments.

Switzerland's Roche, the world's biggest manufacturer of cancer drugs, said the deal will give Genentech rights to Seragon's portfolio of oral drugs under development to treat certain kinds of breast cancer.

The acquisition is for $725 million in cash and up to $1 billion in payments contingent on certain "milestones," Roche said.

7. -- Google (GOOG) reached a deal to acquire Songza, a service that creates soundtracks tailored for people's changing moods.

Financial terms of the deal announced Tuesday were not disclosed. That means the price is considered to be too small to affect Google, which ended March with $59 billion in cash.

8. -- Constellation Brands (STZ), which sells wine, spirits and beer, is expected by analysts on Wednesday to report fiscal first-quarter earnings of 93 cents a share on revenue of $1.43 billion.

9. -- Anthony Noto, the ex-Goldman Sachs investment banker who led Twitter's  (TWTR) initial public offering, is now joining the micro-blogging site as its chief financial officer.

Noto's move comes about six months after Twitter's IPO, and roughly a month after he left Goldman for tech-oriented hedge fund Coatue Management.

Twitter's appointment of Noto as financial chief looks like a move at rebuilding the company's' upper ranks after some big recent departures. Mike Gupta, Twitter's current CFO, will step down from the role to become Twitter's senior vice president of strategic investments.

10. -- One bidder won all of the nearly 30,000 Bitcoins auctioned on Friday by the United States Marshals Service.

"The U.S. Marshals Bitcoin auction resulted in one winning bidder," said Marshals Service spokeswoman Lynzey Donahue. "The transfer of the Bitcoins to the winner was completed (Tuesday)."

The Bitcoins were seized from the now-defunct market Silk Road. 

While the actual price of the winning bid isn't known, the cache sold on June 30 was worth about $19 million at current exchange prices, according to Bloomberg.



Why General Electric Stock Can Still Shock Investors After Alstom 

How GM Could Spin Off a $400 Billion Business  

GoPro's Future Is Foggy Despite Picture-Perfect IPO

-- Written by Joseph Woelfel

To contact the writer of this article, click here:Joseph Woelfel

To submit a news tip, send an email to:tips@thestreet.com.

Follow @josephwoe58

Copyright 2014 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. AP contributed to this report.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,021.77 -17.72 -0.10%
S&P 500 1,991.34 -1.03 -0.05%
NASDAQ 4,544.4090 +12.3050 0.27%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs